Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
FDA breakthrough designation for Bayer and Merck & Co’s AI softwareBayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial Share XFDA breakthrough designation for Bayer and Merck & Co’s AI softwarehttps://pharmaphorum.com/news/fda-breakthrough-designation-bayer-merck-ai/
Bayer/Loxo drug approved in cancers with certain mutationThe FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific Share XBayer/Loxo drug approved in cancers with certain mutationhttps://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
The devil’s in the e-detail: what HCPs really want from youOverview Communication; we all do it, it is a critical part of effective business practice and in this Share XThe devil’s in the e-detail: what HCPs really want from youhttps://pharmaphorum.com/digital/the-devils-in-the-e-detail-what-hcps-really-want-from-you/
Bayer applies artificial intelligence to its pharmacovigilance systemsBayer is looking to accelerate its patient safety data monitoring by using artificial intelligence in a move it Share XBayer applies artificial intelligence to its pharmacovigilance systemshttps://pharmaphorum.com/news/bayer-artificial-intelligence-pharmacovigilance/
Bayer plans filings for prostate cancer drug darolutamideBayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped Share XBayer plans filings for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-plans-filings-for-prostate-cancer-drug-darolutamide/
Novartis, Bayer consider appeal as court says Avastin can be used in AMDEngland’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in Share XNovartis, Bayer consider appeal as court says Avastin can be used in AMDhttps://pharmaphorum.com/news/novartis-bayer-consider-appeal-as-court-says-avastin-can-be-used-in-amd/
EU regulators back Ipsen cancer drug in new liver cancer useIpsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed Share XEU regulators back Ipsen cancer drug in new liver cancer usehttps://pharmaphorum.com/news/eu-regulators-cabometyx-liver/
LEO Pharma acquires Bayer’s dermatology unitDanish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer’s global Share XLEO Pharma acquires Bayer’s dermatology unithttps://pharmaphorum.com/news/leo-pharma-acquires-bayers-dermatology-unit/
